Brummelkamp has gained national and international scientific recognition as a researcher in experimental biomedical genetics. He has developed widely used techniques to study gene function and has applied these to characterize numerous cellular processes. Brummelkamp conducted his PhD research under the supervision of Prof. dr. René Bernards at the NKI and started his own research group at the Whitehead Institute for Biomedical Research in Cambridge (USA). His research group relocated to the NKI in 2011. In addition to his role at the NKI, he is a professor at Utrecht University, a member of the Oncode Institute, and a member of the Royal Netherlands Academy of Arts and Sciences. Alongside his academic work, he co-founded Scenic Biotech, a company focused on genetic modifiers, and is currently establishing a company focused on a new class of tumor antigens.
“At the Netherlands Cancer Institute, we believe that the problem of cancer can be solved through high-quality research and sharing expertise throughout the entire chain. We know that appointing Thijn Brummelkamp means that our key values will be safeguarded over the coming years. He has been deeply involved with our organization for years. We are overjoyed to be able to add a scientist of his caliber to our Executive Board”, says Piet van der Slikke, head of the Supervisory Board of the Netherlands Cancer Institute.
Maurice van den Bosch, chair of the Executive Board, adds: “The Executive Board is very proud to welcome Thijn to our team. This appointment highlights the importance of fundamental research for improved cancer treatments in the future. Thijn will use his collaborative qualities to strengthen the connection between lab and clinic – within our institute as well as beyond. Because only when we work together can we contribute to our mission: a cure for every cancer and excellent care for every patient.”
Brummelkamp will start in his new role on December 1, 2024, and will continue to lead his own research group at the NKI.